Paul Mampilly works as a Senior Editor of Profits Unlimited, which is a newsletter, published by Banyan Hill Publishing that advises subscribers on the stocks that are likely to do well in the future. He is also the editor of other papers like Extreme Fortunes and True Momentum. He attended Fordham University from where he has an MBA. He proceeded to work for Deutsche Bank as an assistant portfolio manager from 1991. He gained invaluable experience in investing the finance and stock market. Kinetics Asset Management hired him to manage its hedge fund. Paul achieved overwhelming success by growing the company’s assets to $25 billion from $6 billion. In 2012, Paul Mampilly invested in Sarepta Therapeutics when the firm was developing a muscular dystrophy drug. After only a year he had gained over 2,000%.
He left the hedge fund job at the age of 42 to spend more time with family and became a research and investment analyst. This way, he can do what he enjoys most, helping everyday people make money. With his experience in the financial world, spanning over 25 years, he tries to teach ordinary guys how to maximize their resources to get the highest returns possible. His newsletters provide helpful investment tips that can lead to success for anybody. Paul Mampilly often appears on Bloomberg TV, CNBC and Fox Business News where he also offers pieces of advice.
Paul Mampilly has written a piece advising on how to know what stocks to buy and when to buy. He believes new investors should focus on technology and innovative ideas. He predicts that the electric vehicles market could shoot so high shortly. For this reason, many people will prefer electric cars over those running on gasoline. The resulting factor is highly profitable stocks, and learn more about Paul Mampilly.
Another area where one can invest is in precision medicine. Paul believes in precision medicine as a way of accurately diagnosing diseases including cancer by genetic testing. Precision medicine involves coming up with the right medication to treat each according to their DNA as opposed to guessing a drug for them. Paul Mampilly therefore, suggests that people should buy stocks from companies dealing in generic testing as they could reap massively in future, and http://reporterexpert.com/paul-mampilly-financial-guru-helping-main-street-americans-invest.
Paul Mampilly does not invest for his subscribers. Instead, he lets them purchase stocks on their own using their brokerage accounts hence limiting interference. He has over 60, 000 subscribers to his publications. Between 2008 and 2009, he won the prestigious Templeton Foundation award when an account he managed got returns of 76%.